Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genentech
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study examining the treatment effect and Safety of GDC-0853 when compared With Placebo and a biologic therapy (Adalimumab) in Rheumatoid Arthritis Patients who have not responded to Previous therapies
• To evaluate the efficacy and safety of GDC-0853 compared with placebo used in combination with stable doses of methotrexate (MTX) in patients (Pts) with active RA who have had an inadequate response...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20, B CELL NON HODGKINS LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
phase II: to evaluate the safety of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL who have progressed following stable disease o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
A trial looking at GDC0941 and anastrozole for oestrogen positive breast cancer (OPPORTUNE)
http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-gdc0941-anastrozole-oestrogen-positive-breast-cancer-opportune ?
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Uncontrolled Severe Asthma
• To evaluate the efficacy of MSTT1041A compared with placebo
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
FIGARO : Essai de phase 2 randomisé, en double aveugle, évaluant la tolérance et l’efficacité des associations carboplatine/paclitaxel et carboplatine/paclitaxel/bévacizumab, avec ou sans GDC-0941, chez des patients ayant un cancer du poumon non à petites cellules avancé ou récurrent, non précédemment traité. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance et l’efficacité des associations carboplatine-paclitaxel et carboplatine-paclitaxel-bévacizumab, avec ou sans GDC-0941, chez des patients ayant un ca...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC- 0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effective
•To evaluate the efficacy (as measured by PFS) of fulvestrant + GDC-0941 versus fulvestrant + placebo •To evaluate the safety of fulvestrant+GDC 0941 and fulvestrant + GDC 0980 versus fulvestrant + p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A study to evaluate the long term safety of rhuMab Beta7 in patients with moderate to severe ulcerative colitis (a form of inflammatory bowel disease) Estudio para evaluar la seguridad de rhuMab Beta7 a largo plazo en pacientes con colitis ulcerosa moderada o grave (una forma de enfermedad inflamatoria del intestino)
To assess the long-term safety and tolerability of rhuMAb Beta7, as measured by adverse events, immunogenicity and safety laboratory parameters, over an extended 2 year treatment period Evaluar ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Étude GO29674 : étude de phase 1, en escalade de dose, évaluant la tolérance de de l'association MOXR0916, un anticorps anti-OX40 avec l’Atezolizumab (MPDL3280a), un anticorps anti-PD-L1, chez des patients ayant une tumeur solide localement avancées ou métastatiques. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
GO29674 : Etude d'escalade de dose de phase Ib, en ouvert, visant à évaluer la sécurité et la pharmacocinétique de l'association MOXR0916 avec le MPDL3280a chez les patients présentant des tumeurs sol...
Country
France
organs
Tumeurs solides
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A study of MetMAb in combination with Tarceva administered to patients with non-small cell lung cancer (NSCLC)
The primary objective of this study is to determine whether the combination of onartuzumab + erlotinib is superior (in terms of OS) to placebo + erlotinib after standard platinum-based chemotherapy in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study of DCDT2980S and DCDS4501A Combined with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Safety and tolerability and anti-tumor activity of DCDT2908S combined with Rituximab and DCDS4501A combined with Rituximab.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
Next